Ricorfotide vedotin  (Synonyms: CBP-1008; LDC 10B)

Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma)^[1][2][3].

Ricorfotide vedotin (CBP-1008) shows faster FRα-mediated internalization and cytotoxicity in the presence of TRPV6 than in the absence of TRPV6^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ricorfotide vedotin (CBP-1008) retains and accumulates in tumors with a half-life of over 48 hours^[3].
Ricorfotide vedotin (CBP-1008) has an MTD of 4 mg/kg in mice, 2 mg/kg in rats, and 1 mg/kg in monkeys^[3].
Ricorfotide vedotin (CBP-1008) shows better efficacy in FRα- and TRPV6-positive than in at least one marker-negative ovarian PDX tumors, as well as growth inhibition of FRα⁺/TRPV6⁺ tumors closely correlates with IHC score^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3408.97

C₁₆₂H₂₄₃N₃₉O₄₀S

2082631-84-1

Solid

Light yellow to yellow

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Fu, et al. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?. Acta pharmaceutica Sinica. B. 2023, 13(2), 498–516.  [Content Brief]

  [2]. Gong, et al. First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors. Journal of Clinical Oncology. 2023, 41 (16).

  [3]. Tan, et al. CBP-1008 shows excellent efficacy and desirable drug safety profile in preclinical models. Proceedings of the American Association for Cancer Research Annual Meeting 2022. 2022, 82(12_Suppl).